OCEANSIDE, CA--(Marketwire - Dec 13, 2012) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the signing of an agreement with Serene Medikal Dis Ticaret Limited Sirketi, a dental supply company headquartered in Izmir Turkey for the distribution of Therapeutic Solutions International's AMPSA products in Turkey.
"This sales agreement with Serene Medikal will add additional territory to product distribution for TSI," stated Tim Dixon, CEO of Therapeutic Solutions International, Inc. "Our entry into the Turkish market is part of our program to expand our AMPSA product distribution in Europe and Asia."
Mehmet Suakar, General Manager of Serene Medikal, stated, "Serene Medikal has considerable experience in the medical and dental distribution business, and we are delighted with this new relationship with TSI. We are committed and prepared to sell to Dentists the Migran-X device for the treatment and care of their patients in Turkey."
Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X™ and AMPSA CS™, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X™ and AMPSA CS™ devices are the most effective non-drug FDA cleared dental method of migraine prevention on the market today. Dentists fit the AMPSA devices on patients for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, in order to reduce their migraine signs and symptoms through the reduction of trigeminally innervated muscular activity, and to prevent bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity.
About Serene Medikal
Serene Medikal was established in 1997 for sales and distribution of high quality and unique medical products in the Turkish Medical and Dental Market with an unrivalled reputation for the reliable delivery of quality products and by providing exceptional sales and customer service with an experienced and well-trained sales and service team.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. produces and markets the FDA cleared NTI Tension Suppression System AMPSA devices sold in the United States under the tradename NTI-tss®, and internationally as the Migran-X™ and AMPSA CS™, for the prevention of medically diagnosed migraine pain. The device is the most cost effective, non-drug dental method of migraine prevention on the market today. In clinical trials reviewed by the FDA in 2001, 82% of medically diagnosed migraine sufferers using the Migran-X device averaged a 77% reduction of migraine events in the first eight weeks of use. Successful outcomes are produced by reducing head, neck and jaw muscle contraction intensity by nearly 70%. We also license laboratories to manufacture and sell semi-custom AMPSA devices internationally. Our corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to the need for further financing, our exit from the US market for AMPSA products in 2013, the need to procure additional international distributors, direct competition beginning in 2013, reliance on key personnel, possible introduction of new product lines, and other specific risks set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.